Liver imaging in patients with a history of known or suspected malignancy is important because the liver is a common site of metastatic spread, especially tumours from the colon, lung, pancreas and stomach, and in patients with chronic liver disease who are at risk for developing hepatocellular carcinoma. Since benign liver lesions are common, liverimaging strategies should incorporate liver lesion detection and characterisation. Survey examination in patients with a known extra-hepatic malignancy to exclude the presence of hepatic and extra-hepatic involvement is normally undertaken with a contrast-enhanced computed tomography examination. When patients with hepatic metastases are being considered for metastasesectomy, they undergo a staging examination with contrast-enhanced magnetic resonance imaging (MRI) using tissue-specific contrast agents. Patients with chronic liver disease who are at risk for hepatocellular carcinoma undergo periodic liver screening for focal liver detection, usually with ultrasonography (US) with MRI being used when US is equivocal. Finally, contrast-enhanced MRI with extra-cellular gadolinium chelates is preferred for characterisation of indeterminate hepatic masses with liver biopsy used when tissue diagnosis is needed.

Author

Maria Raquel Oliva and Sanjay Saini

Contact Details

Corresponding address:
Maria Raquel Oliva and Sanjay Saini
Department of Radiology,
Massachusetts General Hospital and Harvard Medical School,
White 270 55 Fruit Street,
Boston, MA 02114, USA

Reference

ICIS Cancer Imaging volume 4
DOI: 10.1102/1470-7330.2004.0011

Date Posted

2 April 2004

Print PDF

Size

1.12 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	4 seconds
ADSL 512Kb/s (Broadband):	17 seconds
64 Kb/s (ISDN):	2 minutes 23 seconds
33.3 Kb/s (Typical Modem):	4 minutes 36 seconds

Screen PDF

Size

359.76 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	5 seconds
64 Kb/s (ISDN):	44 seconds
33.3 Kb/s (Typical Modem):	1 minute 26 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.